Highlights
- Stratos Wealth Partners LTD. reduced its holdings by 6.0% to 2,474 shares.
- Institutional investors own 99.06% of Lantheus.
- Market capitalization stands at $5.70 billion.
Institutional Investments and Market Activity
Lantheus Holdings (NASDAQ:LNTH) operates in the healthcare sector, specializing in diagnostic and therapeutic solutions. Institutional investors play a significant role in the company's ownership, holding 99.06% of its shares. Stratos Wealth Partners LTD. reduced its stake in Lantheus by 6.0% in the fourth quarter, lowering its holdings to 2,474 shares.
Geode Capital Management LLC increased its stake, now holding 1,683,500 shares valued at approximately $184.8 million. Massachusetts Financial Services Co. MA and Empirical Asset Management LLC also acquired new positions in recent quarters. These activities highlight continued institutional participation in the company’s market presence.
Financial Metrics and Market Valuation
Lantheus Holdings opened at $81.96 in its most recent session, with a market capitalization of $5.70 billion. The stock has a P/E ratio of 13.64 and a beta of 0.44. Over the past 12 months, share prices have ranged from $55.01 to $126.89.
Market Activity and Developments
Recent transactions include a director selling 1,000 shares, adjusting ownership by 2.92%. The company continues to expand its product portfolio, maintaining a strong presence in the healthcare sector.
Business Focus and Industry Role
Lantheus Holdings develops, manufactures, and commercializes diagnostic and therapeutic products. Its portfolio includes DEFINITY, TechneLite, Xenon-133, Neurolite, Cardiolite, and PYLARIFY. These products support medical professionals in cardiology and oncology diagnostics, reinforcing the company's position in the medical imaging and radiopharmaceutical industry.